

C2
Cont

38. (amended) The method of Claim 37 wherein the [modulator is an] antibody or fragment thereof [which binds an osteoprotegerin binding protein] is an antagonist antibody.

~~In Claim 39: delete "38" and substitute -- 37 --.~~

~~In Claim 40: delete "38" and substitute -- 37 --.~~

~~In Claim 42: delete "38" and substitute -- 37 --.~~

~~In Claim 44: delete "38" and substitute -- 37 --.~~

~~In Claim 47: delete "38" and substitute -- 37 --.~~

48. (amended) The method of any of Claims 37-47 further comprising administering a bone morphogenic factor [selected from the group consisting of] BMP-1 to BMP-12, transforming growth factor- β , a transforming growth factor- β family member, a fibroblast growth factor selected from the group consisting of FGF-1 to FGF-10, an interleukin-1 inhibitor, a TNF α inhibitor, parathyroid hormone, an E series prostaglandin, a bisphosphonate, or a bone-enhancing mineral.

C3

49. (amended) The method of any of Claims 37-[48] 47 wherein bone resorption is associated with a [the] bone disease [is] selected from the group consisting of osteoporosis, osteomyelitis, hypercalcemia, osteopenia brought on by surgery or steroid administration, Paget's disease, osteonecrosis, bone loss due to rheumatoid arthritis, periodontal bone loss, osteopenia due to immobilization, prosthetic loosening and osteolytic metastasis.

REMARKS

The Claims

Claims 37-49 are currently pending in the application. Applicant respectfully requests the entry of claim amendments which are fully supported in the specification and do not introduce new matter or new issues requiring further search and/or consideration.